Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gemcitabine with or without Pazopanib in Refractory Soft Tissue Sarcoma
NCT01532687Phase 2Completed
- Sponsor
- OHSU Knight Cancer Institute
- Start
- Mar 2012
- Primary completion
- Oct 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of pazopanib in soft tissue sarcoma (STS), sponsored by OHSU Knight Cancer Institute. Started Mar 2012; status: completed.
02
Drugs
pazopanib
03
Conditions
soft tissue sarcoma (STS)
Beyond the preview
Go deeper on NCT01532687.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01532687.